Bli medlem
Bli medlem

Du är här


Moberg Pharma: Redeye: Rx pipeline for free in Moberg Pharma

Following the Q3 2017 report, we have adjusted our forecasts of Moberg
Pharma slightly, which negatively impact the base case fair value. At
current share price levels (SEK 28), we however believe the market
has taken a too pessimistic approach to the pipeline assets, while
overrating the risk of additional financing of the MOB-015 trials.
Read more in the Research Update by Klas Palin:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.